ZappRx Welcomes James Cornicelli as its Vice President of Corporate Strategy to Build Strong Partnerships with BioPharma and Payers

November 14, 2017

JamesCornicelli-web.jpgBoston, MA, November 14, 2017 – ZappRx, a healthcare technology company that reduces the administrative burden associated with prescribing specialty medications, today announced the appointment of James Cornicelli as Vice President of Corporate Strategy. In his new role, Cornicelli will develop and execute the company’s BioPharma and payer partnering strategy. He will also build and lead a team of business development experts to foster existing partnerships and pursue new partners.


Prior to joining ZappRx, Cornicelli spent 13 years at Salix Pharmaceuticals in a variety of commercial leadership roles where he helped build the company into a thriving, high growth, specialty pharmaceutical company, eventually leading the company to be acquired for $15B in 2015.


In 2013, Cornicelli joined UCB Biopharma, a Belgium-based pharmaceutical company. He was the global head of business development for UCB’s Global Immunology and Bone business units where he led strategy development and business development partnering efforts, ranging from discovery platform partnerships to commercial late stage partnerships, including healthcare IT partnering.


“Zoë has built a company with highly dedicated, incredibly bright professionals and I am thrilled to be part of the fast-growing team,” said Cornicelli. “Over the last 18 years, I have been fortunate to work for companies that are relentlessly focused on improving the lives of patients. ZappRx is the perfect continuation of that great cause. Innovative drugs that have the potential to diminish patient suffering, have successfully made it through over ten arduous years of clinical development but, the fact that patients – who are in desperate need of these therapies – cannot gain access, is simply unacceptable. I cannot think of a more important mission in healthcare.”


In addition to the BioPharma and payer partnering strategy, Cornicelli will work with his colleagues on the Executive committee to further build the ZappRx corporate strategy. This strategy will pertain to the important ZappRx platform stakeholders including payers, specialty pharmacies and providers and will ensure a coherent strategy across stakeholder groups.


“James’ dedication and passion for molding startup companies into their full potential is contagious. He is not only an expert within the biopharma world but also a sincere thought leader that is truly here to help us make a difference and improve patients’ lives,” said Zoë Barry, founder and CEO of ZappRx. “Our internal growth over the past year has been aggressive and by bringing James on to guide our BioPharma unit, I’m confident in our ability to completely break down barriers in the space. We have an exciting future and I’m glad James is on board.”


To learn more about ZappRx, its people, culture and the work its doing to improve care for patients in need of specialty prescriptions, please visit them online at


About ZappRx

ZappRx streamlines the complex process required to order specialty medications, increasing efficiencies when collecting and maintaining the myriad requisite information for specialty prescribing — including pharmacy information, payer/prior authorization requirements, and relevant clinical history. ZappRx then enables providers, pharmacists, and payers to digitally interact with one another to fill a prescription, reducing the need for faxes and phone calls. The platform is currently live in three disease areas, including Pulmonary Arterial Hypertension (PAH), Idiopathic Pulmonary Fibrosis (IPF), and Cystic Fibrosis, with plans to expand to support prescribing for other areas, including gastroenterology, rheumatology, neurology, and oncology conditions. Connect with ZappRx on Twitter and LinkedIn.






Matter for ZappRx

Jessica Wolter